NEUROLOGIE PRO PRAXI / Neurol. praxi. 2023;24(6):449-452 / www.neurologiepropraxi.cz 452 PŘEHLEDOVÉ ČLÁNKY Multidisciplinární přístup ke kognitivnímu deficitu u pacientů s roztroušenou sklerózou LITERATURA 1. Ampapa R. Kognitivní dysfunkce u sekundárně progresivní roztroušené sklerózy. Neurol. praxi. 2022;23(3):221-226. doi: 10.36290/neu.2021.094. 2. Beckmann YY, Gelal F, Eren Ş, et al. Diagnostics to Look beyond the Normal Appearing Brain Tissue (NABT)? A Neuroimaging Study of Patients with Primary Headache and NABT Using Magnetization Transfer Imaging and Diffusion Magnetic Resonance. Clin. Neuroradiol. 2013;23(4):277-283. doi: 10.1007/s00062-013-0203-4. 3. Behrangi N, Fischbach F, Kipp M. Mechanism of Siponimod: Anti‑Inflammatory and Neuroprotective Mode of Action. Cells. 2019;8(1):24. doi: 10.3390/cells8010024. 4. Benedict RHB, Amato MP, DeLuca J, et al. Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues. Lancet Neurol. 2020;19(10):860-871. doi: 10.1016/ S1474-4422(20)30277-5. 5. Benedict RHB, DeLuca J, Phillips G, et al. Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis. Mult Scler. 2017;23:721-733. doi: 10.1177/1352458517690821. 6. Benedict RHB, Penner IK, Kappos L, et al. Baseline MRI Predictors of Cognitive Processing Speed in Participants with Secondary Progressive Multiple Sclerosis from the Phase 3 EXPAND study (2275). Neurology. 2021a;96(15 Supplement)2275. 7. Benedict RHB, Tomic D, Cree BA, et al. Siponimod and Cognition in Secondary Progressive Multiple Sclerosis: EXPAND Secondary Analyses. Neurology. 2021 b;96(3):e376-e386. doi: 10.1212/ WNL.0000000000011275. 8. Cavedo E, Tran P, Thoprakarn U, et al. Validation of an automatic tool for the rapid measurement of brain atrophy and white matter hyperintensity: QyScore®. Eur. Radiol. 2022;32(5):29492961. doi: 10.1007/s00330-021-08385-9. 9. Grzegorski T, Losy J. Cognitive impairment in multiple sclerosis - a review of current knowledge and recent research. Rev Neurosci. 2017;28(8):845-860. doi: 10.1515/revneuro-2017-0011. 10. Hynčicová E., Meluzímová E., Laczó J. Kognice a roztroušená skleróza. Neurol. praxi. 2017;18(6):394-398. doi: 10.36290/ neu.2018.055. 11. Kappos L, Bar‑Or A, Cree BAC, et al. EXPAND Clinical Investigators. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double‑blind, randomised, phase 3 study. Lancet. 2018;391(10127):1263-1273. doi: 10.1016/S01406736(18)30475-6. 12. Leavitt VM, Brandstadter R, Fabian M, et al. Dissociable cognitive patterns related to depression and anxiety in multiple sclerosis. Mult Scler. 2020;26(10):1247-1255. doi:10.1177/1352458519860319. 13. Linnhoff S, Fiene M, Heinze HJ, et al. Cognitive Fatigue in Multiple Sclerosis: An Objective Approach to Diagnosis and Treatment by Transcranial Electrical Stimulation. Brain Sci. 2019;9(5):100. doi: 10.3390/brainsci9050100. 14. Papathanasiou A, Messinis L, Georgiou VL, et al. Cognitive impairment in relapsing remitting and secondary progressive multiple sclerosis patients: efficacy of a computerized cognitive screening battery. ISRN Neurol. 2014;2014:151379. doi: 10.1155/2014/151379. 15. Patten SB, Ruth AM, Mauro GC. Depression in multiple sclerosis. Int Rev Psychiatry. 2017;29(5):463-472. doi: 10.1080/09540261.2017.1322555. 16. Petracca M, Saiote C, Bender H, et al. Synchronization and variability imbalance underlie cognitive impairment in primary ‑progressive multiple sclerosis. Sci Rep. 2017;7:46411. doi: 10.1038/ srep46411. 17. Pitteri M, Romualdi C, Magliozzi R, et al. Cognitive impairment predicts disability progression and cortical thinning in MS: An 8-year study. Mult Scler. 2017;23(6):848-854. doi: 10.1177/1352458516665496. 18. Popescu V, Klaver R, Voorn P, et al. What drives MRI‑measured cortical atrophy in multiple sclerosis? Mult. Scler. J. 2015;21(10):12801290. doi: 10.1177/1352458514562440. 19. Rocca MA, Amato MP, De Stefano N, et al. MAGNIMS Study Group. Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis. Lancet Neurol. 2015;14(3):302-17. doi: 10.1016/S1474. 20. Sandroff BM, Schwartz CE, DeLuca J. Measurement and maintenance of reserve in multiple sclerosis. J Neurol. 2016; 263(11):2158-2169. doi: 10.1007/s00415-016-8104-5. 21. Schependom VJ, Nagels G. Targeting Cognitive Impairment in Multiple Sclerosis – The Road toward an Imaging‑based Biomarker. Front. Neurosci. 2017;11. doi: 10.3389/fnins.2017.00380. 22. Stern Y. Cognitive reserve. Neuropsychologia. 2009;47(10):20152028. doi: 10.1016/ j.neuropsychologia.2009. 03. 004. 23. Strádalová P, Štourač P, Králíčková Nekvapilová E. Ochranné faktory kognitivního deficitu u roztroušené sklerózy. Cesk Slov Neurol N. 2018;81(1):24-28. doi: 10.14735/amcsnn201824. 24. Sumowski JF. Cognitive reserve as a useful concept for early intervention research in multiple sclerosis. Front. Neurol. 2015;6:176. doi: 10.3389/fneur.2015.00176. 25. Sumowski JF, Rocca MA, Leavitt VM, et al. Brain reserve against physical disability progression over 5 years in multiple sclerosis. Neurology. 2016;86(21):2006-2009. doi:10.1212/ WNL.0000000000002702. 26. Sumowski JF, Rocca MA, Leavitt VM, et al. Brain reserve and cognitive reserve in multiple sclerosis: what you’ve got and how you use it. Neurology. 2013;80(24):2186-2193. doi: 10.1212/ WNL.0b013e318296e98b. 27. Sumowski JF, Rocca MA, Leavitt VM et al. Brain reserve and cognitive reserve protect against cognitive decline over 4.5 years in MS. Neurology. 2014;82(20):1776-1783. doi: 10.1212/ WNL.0000000000000433. 28. Vaněčková M, Seidl Z, Krásenský J, et al. Naše zkušenosti s MR monitorováním pacientů s roztroušenou sklerózou v klinické praxi. Cesk Slov Neurol N. 2010;73/106(6):716-720. 6. 7. 6. 2024 BRNO 21. sympozium praktické neurologie MÍSTO KONÁNÍ: Hotel International Brno Husova 200/16, 602 00 Brno Aktuální program sledujte na www.neubrno.cz
RkJQdWJsaXNoZXIy NDA4Mjc=